CARRESS HF Trial Summary: Bart et al. randomized 188 patients with decompensated acute heart failure and worsening renal function (Increase in serum creatinine ≥0.3 mg/dL) – [cardiorenal syndrome] to ultrafiltration (fluid removal of 200 mL/hr, n=94) or medical therapy (Protocol driven IV diuresis, n=94). The primary objective was to assess if ultrafiltration improves volume removal, renal function, and reduce HF complications when compared to medical therapy in acutely decompensated heart failure and cardiorenal syndrome. The results showed worsening of change in serum creatinine level and change in weight at day 4 in the ultrafiltration group (P=0.003). The authors of CARRESS HF trial concluded that in patients with acute decompensated HF and cardiorenal syndrome, ultrafiltration is associated with more adverse events, worsening renal function, and no change in weight when compared to medical therapy.

Source: NEJM